TheraRadar
← Back
Data updated: Mar 29, 2026

ALEXION PHARM

ImmunologyCardiovascularMetabolic
Biotech

ALEXION PHARM is a biotechnology company focused on Immunology, Cardiovascular, Metabolic. Key products include STRENSIQ.

2007
Since
4
Drugs
-
Trials
11
Approved (2yr)

Key Drugs

KANUMA
sebelipase alfa
Lysosomal acid lipase 1 indications · 2015
STRENSIQ
asfotase alfa
TNSALP 1 indications · 2015

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

ULTOMIRIS 2025-09-26
Manufacturing (CMC)
SOLIRIS 2025-06-27
REMS
ULTOMIRIS 2025-06-27
REMS
SOLIRIS 2025-02-28
Efficacy
ULTOMIRIS 2025-02-28
REMS
SOLIRIS 2024-09-19
Labeling
ULTOMIRIS 2024-09-19
Labeling
KANUMA 2024-07-10
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Immunology 38%
0 drugs Phase 2: 5 Phase 1: 1
Cardiovascular 17%
0 drugs Phase 3: 1 Phase 1: 1
Metabolic 17%
0 drugs Phase 3: 1 Phase 1: 1
Respiratory 14%
0 drugs Phase 3: 1
Gastroenterology 14%
0 drugs Phase 2: 1 Phase 1: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

AstraZeneca big-pharma
Respiratory, Cardiovascular, Metabolic, Immunology
Novartis big-pharma
Cardiovascular, Immunology, Respiratory
Boehringer Ingelheim big-pharma
Metabolic, Respiratory, Immunology, Cardiovascular
Merck big-pharma
Cardiovascular, Immunology, Metabolic
Johnson & Johnson big-pharma
Immunology, Cardiovascular, Metabolic